Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rameen Beroukhim, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Rameen Beroukhim and Gad Getz.
Connection Strength

1.996
  1. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591.
    View in: PubMed
    Score: 0.198
  2. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
    View in: PubMed
    Score: 0.146
  3. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
    View in: PubMed
    Score: 0.139
  4. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21.
    View in: PubMed
    Score: 0.132
  5. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41.
    View in: PubMed
    Score: 0.123
  6. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.113
  7. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.097
  8. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.071
  9. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 02; 34(5):108707.
    View in: PubMed
    Score: 0.061
  10. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 02; 578(7793):102-111.
    View in: PubMed
    Score: 0.057
  11. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
    View in: PubMed
    Score: 0.051
  12. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
    View in: PubMed
    Score: 0.051
  13. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
    View in: PubMed
    Score: 0.051
  14. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19.
    View in: PubMed
    Score: 0.050
  15. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
    View in: PubMed
    Score: 0.050
  16. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.050
  17. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
    View in: PubMed
    Score: 0.045
  18. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16.
    View in: PubMed
    Score: 0.045
  19. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 08; 48(8):848-55.
    View in: PubMed
    Score: 0.044
  20. Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46.
    View in: PubMed
    Score: 0.043
  21. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.042
  22. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 2015 Nov; 25(11):1634-45.
    View in: PubMed
    Score: 0.042
  23. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
    View in: PubMed
    Score: 0.037
  24. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
    View in: PubMed
    Score: 0.035
  25. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013 May; 45(5):478-86.
    View in: PubMed
    Score: 0.035
  26. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
    View in: PubMed
    Score: 0.034
  27. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.033
  28. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
    View in: PubMed
    Score: 0.029
  29. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.025
  30. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.024
  31. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
    View in: PubMed
    Score: 0.023
  32. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.